ImmunityBio Inc (NASDAQ:IBRX)’s traded shares stood at 12.3 million during the latest session, with the company’s beta value hitting 0.90. At the last check today, the stock’s price was $5.42, to imply an increase of 28.77% or $1.21 in intraday trading. The IBRX share’s 52-week high remains $10.53, putting it -94.28% down since that peak but still an impressive 71.22% since price per share fell to its 52-week low of $1.56. The company has a valuation of $3.78B, with an average of 3.35 million shares in intraday trading volume over the past 10 days and average of 2.95 million shares over the past 3 months.
Analysts have given a consensus recommendation of Sell for ImmunityBio Inc (IBRX), translating to a mean rating of 1.67. Of 1 analyst(s) looking at the stock, 1 analyst(s) give IBRX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 0 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ImmunityBio Inc (NASDAQ:IBRX) trade information
After registering a 28.77% upside in the latest session, ImmunityBio Inc (IBRX) has traded red over the past five days. The 5-day price performance for the stock is 52.71%, and 39.01% over 30 days. With these gigs, the year-to-date price performance is 7.99%. Short interest in ImmunityBio Inc (NASDAQ:IBRX) saw shorts transact 52.68 million shares and set a 18.91 days time to cover.
The extremes give us $8 and $8 for target low and target high price respectively. As such, IBRX has been trading -47.6% off suggested target high and -47.6% from its likely low.
ImmunityBio Inc (IBRX) estimates and forecasts
Looking at statistics comparing ImmunityBio Inc share performance against respective industry, we note that the company has underperformed competitors. ImmunityBio Inc (IBRX) shares are -26.24% down over the last 6 months, with its year-to-date growth rate lower than industry average at 13.13% against 17.50%.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 1.17% for the past 5-year period. While 2024 is set for a 28.66% return in earnings, projections for the next 5 years are at -1.70% annually.
IBRX Dividends
ImmunityBio Inc has its next earnings report out on 2024-Nov-06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
ImmunityBio Inc insiders hold 77.04% of total outstanding shares, with institutional holders owning 9.13% of the shares at 39.75% float percentage. In total, 9.13% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 13.83 million shares (or 2.0558% of shares), all amounting to roughly $87.42 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 11.42 million shares, or about 1.6978% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $72.19 million.
